Myofibrillogenesis regulator 1 (MR-1): a potential therapeutic target for cancer and PNKD

References

• Li TB, Liu XH, Feng S, et al. Characterization of MR-1, a novel myofibrillogenesis regulator in human muscle. Acta Biochim Biophys Sin (Shanghai). 2004;36:412–418.
   PubMed Web of Science ®Google Scholar
• Lee HY, Xu Y, Huang Y, et al. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet. 2004;13:3161–3170.
   PubMed Web of Science ®Google Scholar
• Nagao M, Fujita Y, Sugimura T, et al. Methylglyoxal in beverages and foods: its mutagenicity and carcinogenicity. IARC Sci Publ. 1986;70:283.
   Google Scholar
• Bushell M. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ. 2000;7:603–615.
   PubMed Web of Science ®Google Scholar
• Gao M, Guo KM, Wei YM, et al. Aspirin inhibits the proliferation of human uterine leiomyoma cells by downregulation of KRasp110alpha interaction. Oncol Rep. 2017;38:2507–2517.
   PubMed Web of Science ®Google Scholar
• Qiu W, Xia X, Qiu Z, et al. RasGRP3 controls cell proliferation and migration in papillary thyroid cancer by regulating the Akt-MDM2 pathway. Gene. 2017;633:35–41.
   PubMed Web of Science ®Google Scholar
• Zolfaghari N, Shahbazi S, Torfeh M, et al. Identification of differentially expressed K-Ras transcript variants in patients with leiomyoma. Reprod Sci. 2017;24:1438–1443.
   PubMed Web of Science ®Google Scholar
• Ghezzi D, Viscomi C, Ferlini A, et al. Paroxysmal non-kinesigenic dyskinesia is caused by mutations of the MR-1 mitochondrial targeting sequence. Hum Mol Genet. 2009;18:1058–1064.
   PubMed Web of Science ®Google Scholar
• Shen Y, Lee HY, Rawson J, et al. Mutations in PNKD causing paroxysmal dyskinesia alters protein cleavage and stability. Hum Mol Genet. 2011;20:2322–2332.
   PubMed Web of Science ®Google Scholar
• Lu R, Sun M, Feng J, et al. Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer. 2011;11:270.
   PubMed Web of Science ®Google Scholar
• Gong Y, He H, Liu H, et al. Phosphorylation of myofibrillogenesis regulator-1 activates the MAPK signaling pathway and induces proliferation and migration in human breast cancer MCF7 cells. FEBS Lett. 2014;588:2903–2910.
   PubMed Web of Science ®Google Scholar
• Bruno MK, Lee HY, Auburger GW, et al. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology. 2007;68:1782–1789.
   PubMed Web of Science ®Google Scholar
• Shimojima K, Okumura A, Natsume J, et al. Spinocerebellar ataxias type 27 derived from a disruption of the fibroblast growth factor 14 gene with mimicking phenotype of paroxysmal non-kinesigenic dyskinesia. Brain Dev. 2012;34:230–233.
   PubMed Web of Science ®Google Scholar
• Frey N, Katus HA, Olson EN, et al. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580–1589.
   PubMed Web of Science ®Google Scholar
• Epstein JA, Parmacek M. S Recent advances in cardiac development with therapeutic implications for adult cardiovascular disease. Circulation. 2005;112:592–597.
   PubMed Web of Science ®Google Scholar
• Liu X, Li T, Sun S, et al. Role of myofibrillogenesis regulator-1 in myocardial hypertrophy. Am J Physiol Heart Circ Physiol. 2006;290:H279–H285.
   PubMed Web of Science ®Google Scholar
• Ichihara S, Senbonmatsu T, Price E Jr, et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation. 2001;104:346–351.
   PubMed Web of Science ®Google Scholar
• Dai W, He W, Shang G, et al. Gene silencing of myofibrillogenesis regulator-1 by adenovirus-delivered small interfering RNA suppresses cardiac hypertrophy induced by angiotensin II in mice. Am J Physiol Heart Circ Physiol. 2010;299:H1468–H1475.
   PubMed Web of Science ®Google Scholar
• Li HL, She ZG, Li TB, et al. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension. 2007;49:1399–1408.
   PubMed Web of Science ®Google Scholar
• Dai W, Chen H, Jiang J, et al. Silencing MR-1 attenuates inflammatory damage in mice heart induced by AngII. Biochem Biophys Res Commun. 2010;391:1573–1578.
   PubMed Web of Science ®Google Scholar
• Ren K, Jin H, Bian C, et al. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J Biol Chem. 2008;283:35598–35605.
   PubMed Web of Science ®Google Scholar
• Guo J, Dong B, Ji JF, et al. Myofibrillogenesis regulator-1 overexpression is associated with poor prognosis of gastric cancer patients. World J Gastroenterol. 2012;18:5434–5441.
   PubMed Web of Science ®Google Scholar
• Lu RQ, Sun M, Gao X, et al. [Expression of a novel biomarker, MR-1S, in ovarian carcinoma and its biological significance]. Zhonghua Zhong Liu Za Zhi. 2012;34:176–181.
   PubMedGoogle Scholar
• Zhao CY, Guo ZJ, Dai SM, et al. Clinicopathological and prognostic significance of myofibrillogenesis regulator-1 protein expression in pancreatic ductal adenocarcinoma. Tumour Biol. 2013;34:2983–2987.
   PubMedGoogle Scholar
• Zhao W, He H, Ren K, et al. MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation. Blood Cancer J. 2013;3:e107.
   PubMed Web of Science ®Google Scholar
• Wang C, Xiang H, Si H, et al. High expression of myofibrillogenesis regulator-1 predicts poor prognosis for patients with hepatocellular carcinoma after curative hepatectomy. Int J Clin Exp Pathol. 2015;8:14818–14823.
   PubMed Web of Science ®Google Scholar
• Wilson AK, Pollenz RS, Chisholm RL, et al. The role of myosin I and II in cell motility. Cancer Metastasis Rev. 1992;11:79–91.
   PubMed Web of Science ®Google Scholar
• Owen JD, Ruest PJ, Fry DW, et al. Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol. 1999;19:4806–4818.
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Watanabe S, Matsumoto Y, et al. FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. J Biol Chem. 1999;274:10566–10570.
   PubMed Web of Science ®Google Scholar
• Zhao W, He H, Ren K, et al. Myofibrillogenesis regulator-1 promotes cell adhesion and migration in human hepatoma cells. Chin Sci Bull. 2013;58:3007–3014.
   Google Scholar
• Mcwhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13:7587–7595.
   PubMed Web of Science ®Google Scholar
• Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev. 1997;8:63–79.
   PubMedGoogle Scholar
• Hochhaus A, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up. Ann Oncol. 2008;19(2):ii63–ii64.
   Google Scholar
• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2007;103:4010–4022.
   Google Scholar